

sparc

Update on Clinical Programs and R&D Pipeline

Nov 2, 2023

BSE: 532872
NSE: SPARC BLOOMBERG: SPADV@IN RETURNS: SPRC.BO
CIN: L73100GI2006PLC047837

Disclaimer

This presentation and its contents should not be distributed, published or reproduced, in whole or part, or disclosed by recipients directly or indirectly to any other person. Any failure to comply with these restrictions may constitute a violation of applicable laws. Accordingly, any persons in possession of this presentation should inform themselves about and observe any such restrictions. This presentation may include statements which may constitute forward-looking statements. All statements that address expectations or projections about the future, including, but not limited to, statements about the strategy for growth, business development, market position, expenditures, and financial results, are forward looking statements. Peak sales forecast/potential in the presentation represent potential sales of the product/s for the commercialization partner. Forward looking statements are based on certain assumptions and expectations of future events. This presentation should not be relied upon as a recommendation or forecast by Sun Pharma Advanced Research Company Limited ("Company"). Please note that the past performance of the Company is not, and should not be considered as, indicative of future results. The Company cannot guarantee that these assumptions and expectations are accurate or will be realized. The actual results, performance or achievements, could thus differ materially from those projected in any such forward-looking statements. The Company does not undertake to revise any forward-looking statement that may be made from time to time by or on behalf of the Company. Given these risks, uncertainties and other factors, viewers of this presentation are cautioned not to place undue reliance on these forward looking statements.

The information contained in these materials has not been independently verified. None of the Company, its Directors, Promoters or affiliates, nor any of its or their respective employees, advisers or representatives or any other person accepts any responsibility or liability whatsoever, whether arising in tort, contract or otherwise, for any errors, omissions or inaccuracies in such information or opinions or for any loss, cost or damage suffered or incurred howsoever arising, directly or indirectly, from any use of this document or its contents or otherwise in connection with this document, and makes no representation or warranty, express or implied, for the contents of this document including its accuracy, fairness, completeness or verification or for any other statement made or purported to be made by any of them, or on behalf of them, and nothing in this presentation shall be relied upon as a promise or representation in this respect, whether as to the past or the future. The information and opinions contained in this presentation are current, and if not stated otherwise, as of the date of this presentation. The Company undertakes no obligation to update or revise any information or the opinions expressed in this presentation as a result of new information, future events or otherwise. Any opinions or information expressed in this presentation are subject to change without notice. This presentation does not constitute or form part of any offer or invitation or inducement to sell or issue, or any solicitation of any offer to purchase or subscribe for, any securities of the Company, nor shall it or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any contract or commitment therefor. No person is authorized to give any information or to make any representation not contained in or inconsistent with this presentation and if given or made, such information or representation must not be relied upon as having been authorized by any person. By participating in this presentation or by accepting any copy of the slides presented, you agree to be bound by the foregoing limitations. All brand names and trademarks are the property of respective owners.

Agenda

01 Strategic Overview

Anil Raghavan

02 Clinical Programs

Siu-Long Yao

03 SCD-153

Vikram Ramanathan

04 SBO-154

Nitin Damle

05 Financial Update

Chetan Rajpara

sparc

Strategic overview

Anil Raghavan

Maturing portfolio & operating model

Cost competitive translation with global access to science

- Pivot from 505(b)2
- Embrace risk
- Scalable platforms

- Oncology, Neurology & Immunology
- Focus on specific pathways & approaches

- Competency development
- Sharper execution focus

- Plug into global innovation ecosystem

- Rigorous review and prioritization
- External engagement

- In-house competencies and infrastructure to prosecute an idea from 'bench to bedside' with an ability to scale across modalities
- 3 NDAs approved by the USFDA and commercialized by partners, contributing significant 'non dilutive' cash to support the portfolio and operating model build-up
- Robust pipeline with 3 NCEs under clinical development in 6 indications including two 'first-in-class' opportunities

NDA: New Drug Application| USFDA: United States Food & Drug Administration | NCE: New Chemical Entity

Year 2024 promises several value inflection points

High-yield assets set to read out clinical PoCs and proceed to pivotal programs

- Key catalytic events coming up every quarter during next year

Q1 2024

Vodobatinib PD

PROSEEK Interim analysis readout

Q2 2024

SCD-153

Phase 1 SAD study results

Vibozilimod*

Atopic dermatitis

Phase 2 study enrollment completion

Q3 2024

Vodobatinib PD

PROSEEK full data readout

Q4 2024

SBO-154

IND submission

Vibozilimod*

Atopic dermatitis

Interim analysis and topline results

SCD-153

Phase 1 MAD study initiation

PoC: Proof of Concept I PROSEEK: Phase 2 study in early Parkinson's disease patients evaluating the safety and efficacy of Abl tyrosine kinase inhibition using K0706 I PD: Parkinson's Disease I SAD: Single Ascending Dose I MAD: Multiple Ascending Dose I IND: Investigational New Drug I *Vibozilimod licensed to Sun Pharmaceutical Industries Limited

Vodobatinib reached Phase 2 enrollment target

PROSEEK read out to provide definitive PoC for the cAbl hypothesis and oxidative stress response modulation as an approach for neuroprotection

PROSEEK

Phase 2 study of Abl tyrosine kinase inhibition with Vodobatinib

- One of the largest Phase 2 study ongoing for early PD patients (pre L-Dopa)
  - **Study met enrollment target, 504 evaluable patients**
  - Treatment duration of 40 weeks followed by 40 weeks' extension study
  - Data from interim analysis expected in March 2024
- Geared up for post PROSEEK outcome
  - State of readiness for initiation of Phase 3 study
  - Engaging partners for potential collaboration



Oxidative stress in PD and related α-synucleinopathies[1]

Data cut-off: 20 Oct 2023

1. c-Abl and Parkinson's Disease: Mechanisms and Therapeutic Potential - J Parkinsons Dis. 2017; 7(4): 589–601

cAbl: Cellular Abelson Kinase | L-Dopa: Levodopa

PROSEEK opens up a broad opportunity set

Unlocks significant value for SPARC with potential use across PD progression and in disorders driven by α-synuclein

- Potential to combine with symptomatic therapies in PD
- Potential for early interventions in precursor conditions
- PROSEEK offers a powerful PoC for the pathway in diseases driven by α-synuclein
- Key disorders having α-synuclein aggregation as a pivotal process include PD, MSA & DLB



Vodobatinib can emerge as the protective backbone across the continuum of care for synucleopathies and other neurodegenerative disorders resulting from misfolded proteins

Chart adapted from Is insulin-like growth factor-1 involved in Parkinson's disease development? Castilla-Cortázar et al. J Transl Med (2020) 18:70
MSA: Multiple System Atrophy | DLB: Dementia with Lewy Bodies | OCD: Obsessive Compulsive Disorder

Optionality beyond PROSEEK

SPARC pipeline includes multiple high value assets with platform potential

- SPARC's immunology program will provide additional efficacy and safety data points in 2024
- Oncology offers a potential hedge and anchor for future portfolio build across modalities
- Additional bets to understand underlying mechanisms in neurodegenerative diseases - UK DRI collaboration

Immunology

- Led by 3rd generation S1PR1 agonist, Vibozilimod with potential to be best-in-class asset in Dermatology – Clinical PoC in 2024
- SCD-153 program to explore a novel pathway with a topical agent for Alopecia Areata – Safety PoC in 2024
- Potential additional indications

Oncology

- Vodobatinib in CML – Recalibrating to a changing regulatory and market landscape
- MUC-1 program – A differentiated targeting approach which can become a pipeline in itself beyond the first ADC
- UCSF collaboration for Small Molecule Drug Conjugates in mPC
- Strong preclinical interest in antibody mediated delivery, RNA targeted therapeutics, & collateral lethality

Additional shots on goal & enabling competencies differentiate SPARC's risk profile

UKDRI: UK Dementia Research Institute | S1PR1: Sphingosine-1-Phosphate Receptor 1 | CML: Chronic Myelogenous Leukemia | MUC-1: Mucin-1 | ADC: Antibody Drug Conjugate | UCSF: University of California San Francisco | mPC: metastatic Prostate Cancer | RNA: Ribonucleic Acid

Immunology program focused on autoimmune disorders in dermatology

Opportunity to become safer oral alternative to the current SoC; offers a path to build an immunology franchise

Vibozilimod

- Two Phase 2b studies recruiting patients in Psoriasis and Atopic Dermatitis; lead indication Atopic Dermatitis
- Provides an alternate mechanism to IL-4/IL-13 antibodies and JAK inhibitors
- Studies being expanded to Europe and Canada

SCD-153

- Topical application may potentially provide a safer alternative to currently approved JAK inhibitors for treatment of AA
- Phase 1 study initiated for AA
- Preclinical evaluation ongoing in other autoimmune diseases of epidermis

SoC: Standard of Care | IL-4: Interleukin-4 | IL-13: Interleukin-13 | JAK: Janus Kinase | AA: Alopecia Areata

Oncology pipeline with multiple near-term clinical options…

…backed up by an active preclinical effort involving multiple targets and modalities

- Vodobatinib for CML (SCO-088) writes down the PROSEEK risk
  - Validated target; efficacy established in patients
  - Being developed under Frontrunner program of the USFDA; potential to move in earlier lines of treatment

Cell-targeting by ADC[1]



- Antibody and small molecule ligands targeted delivery of payloads across modalities is a key focus for SPARC oncology
  - MUC-1 antibody provides a differentiated platform to build pipeline of assets targeting a defined subset of patients across multiple tumors
  - Key elements of the MUC-1 α/β hypothesis validated. First program on track; expected to enter clinic in 2024
  - Additional constructs with other payloads and augmented targeting are being evaluated in preclinical setting
  - Preclinical PoC established for Small Molecule Drug Conjugate
- Emerging preclinical interest in novel synthetic lethality pairings and RNA therapeutics

1. Adapted from: Antibody-drug conjugates for cancer Cindy C et al. Lancet 2019;394:793-804

Rigorous translational focus

Focused on patient needs, developability considerations & asset appropriateness

- Rigorous portfolio review process – Kill early, kill cheap, kill completely
- Large proportion of programs focusing on novel biology (potential first-in-class). Continued development of best-in-class assets for validated targets to balance the risk

SPARC expects additional non-dilutive cash flows from its commercial/partnered assets

ELEPSIA & XELPROS

- Strong uptake post launch
- Commercialization disrupted due to import alert at partner's manufacturing site
- Identified alternate manufacturing site for tech transfer

SEZABY

- Licensed to SPI Inc.
- Safeguarding interests of patients and caregivers
  - Filed PIL with USFDA
  - Sent cease & desist letters to companies marketing unapproved products in the US market
  - Robust supply chain development

PDP-716

- USFDA issued CRL to PDP-716 NDA due to inspection findings at a third-party API manufacturing facility
- No additional clinical data or trials requested
- Identified alternate API partner

VIBOZILIMOD

- SPARC eligible to receive regulatory & sales milestones and royalty on sales
- Option to monetize royalty for immediate fund requirements

SPI: Sun Pharmaceutical Industries | PIL: Public Interest Litigation | CRL: Complete Response Letter | API: Active Pharmaceutical Ingredient | NDA: New Drug Application

Pipeline overview



Bexirestrant deprioritized based on commercial assessment and change in treatment landscape

1. Investor initiated study.
MoA: Mechanism of Action | BCR-ABL: Breakpoint Cluster Region-Abelson

Key priorities for next year

Execution focus is the objective

Clinical studies

- PROSEEK completion and data readout
- Vodobatinib Phase 3 study initiation for PD
- SCD-153 Phase 2 study initiation
- Vibozilimod enrollment completion for Atopic Dermatitis study

Regulatory filing

- Elepsia site transfer
- PDP-716 re-filing
- EoP2 meeting with USFDA for Vodobatinib in neurodegenerative disorders
- SBO-154 IND filing

Strategic priorities

- Resourcing to ensure smooth operations
- In-licensing of potential opportunities
- Capabilities and resource building

EoP2: End of Phase 2

sparc

Clinical programs

Siu-Long Yao

sparc

Vodobatinib (SCC-138) for neurodegenerative diseases

Siu-Long Yao

Parkinson's disease epidemiology

PD affects ~7 mn people globally; expected to grow above 14 mn by 2040

- PD population outgrowing overall population (2-4% growth in PD vs. 1% global population growth)
- DMTs can make significant impact to the lives of PD patients by changing the trajectory of disease



1. Update on the diagnosis and management of Parkinson's disease. Kobylecki C. Clinical Medicine. 2020 Jul;20(4):393.
IQVIA-SPARC-Vodobatinib Opportunity Assessment in PD-Final Readout-September 2020
Source: IQVIA analysis; population and growth rate: Census, Eurostat, INSEE, Word Bank, Parkinson's Foundation, Savica et al, JAMA Neurology, 2017
DMT: Disease Modifying Therapy

PROSEEK study update

Enrollment target met



Part 1

- Data from interim analysis expected to be available by March 2024

Part 2

- Study initiated in Q4 2021
- ~87% of eligible patients enrolled in Part 2
- Continuing treatment for additional 9 months
- Continues to evaluate patients until May 2025

Data cut-off: 20 October 2023

PROSEEK study update

No significant cardiac events reported in the patients recruited



- Over 40% patients enrolled from the US
- Grade 3/4 events reported in 6.1% patients
- GI and rash were the most common AEs reported
- No changes in study protocol recommended by DSMB throughout the conduct of the study
  - 6 DSMB reviews conducted

DSMB: Data and Safety Monitoring Board | GI: Gastrointestinal | AE: Adverse Events
Data cut-off: 20 October 2023

PROSEEK study update

Biomarkers under evaluation

- Target biomarker cohort enrolment – 150 total (random assignment)
- Further randomization to placebo, low dose, or high dose Vodobatinib – 50 assigned to each arm
- Exploratory samples (CSF, plasma, serum) at baseline, 8 & 40 weeks (EOT)

Trial Entrance/Exit

- DaT-SPECT Scan
- α-Synuclein skin biopsy

Target Engagement

- c-ABL and CRKL

Neuronal Death

- Neurofilament Light

PD/Efficacy

- Downstream targets (AIMP2, NFκB, NLRP3, p38α[MAPK], PARIS, Parkin, α-synuclein)

Motion/Gait Sensing

- Phone based assessment

CSF: Cerebrospinal Fluid IEOT: End of Treatment| DaT-SPECT: Dopamine Transporter Single-photon Emission Computed Tomography | CRKL: CT10 Regulator of Kinase Like | NFκB: Nuclear Factor kappa B NLRP3: Nucleotide-binding domain, Leucine-Rich-containing family, Pyrin domain-containing-3 | MAPK: Mitogen-Activated Protein Kinases | PARIS: Parkin Interacting Substrate | AIMP2: Aminoacyl TRNA Synthetase Complex Interacting Multifunctional Protein 2

Vodobatinib development

Activities running in parallel before EoP2 meeting with FDA



EoP2 meeting with FDA planned in Nov 2024

BA: Bioavailability I DDI: Drug-Drug Interaction I hADME: human Absorption Distribution Metabolism Excretion

Opportunities beyond Parkinson's disease

Vodobatinib reduces the intracellular load of potentially toxic proteins in iPSC - induced neurons





Vodobatinib downregulates key proteins associated with development of synucleopathies and tauopathies*

The concept of α-Synuclein strains and how different conformations may explain distinct neurodegenerative disorders. Katja M et.al. Frontiers in Neurology. 2021
*Study conducted at Brigham and Women's Hospital Boston
iPSC: induced Pluripotent Stem Cells | PD: Parkinson's Disease | DLB: Dementia with Lewy Bodies | MSA: Multiple System Atrophy | iRBD: idiopathic Rapid eye movement Behavior Disorder | PAF: Pure Autonomic Failure | DMSO: Dimethyl Sulfoxide | cABL: cellular Abelson kinase | Lamp 1: Lysosomal-associated membrane protein 1

Vodobatinib (SC0-088) for chronic myeloid leukemia

Siu-Long Yao

Chronic myeloid leukemia

Use of 2nd and 3rd generation agents increasing





- The prevalence of CML is estimated to grow primarily attributed to prolonged survival and access to TKIs
- The current value market is over US$ 3.5 bn

1. www.seer.cancer.gov/statfacts/html/cmyl.html
2. IQVIA MAT July
TKI: Tyrosine Kinase Inhibitors

Vodobatinib (SCO-088) Phase 1/2 study results

sparc

Patients continue to benefit over a long period of time



- Over 1/3rd patients on study drug beyond 3 years
- Median duration on study drug being 32.3 months (range: 0.3 – 73.4 months)

*Best response
CML-CP: Chronic Myelogenous Leukemia - Chronic Phase
Values are rounded-off
Data cut-off: 20 Oct 2023

Preclinical data confirms superiority of Vodobatinib over 2nd generation TKI

Anti-leukemic activity in Ba/F3-WT xenografts



- Vodobatinib demonstrated better growth inhibition (GI50) over nilotinib in Ba/F3 BCR::ABL1 wildtype (WT) and its resistant mutants *in-vitro*
- Vodobatinib has better antitumor activity over nilotinib *in-vivo*

Nilotinib administered in mice at doses that give exposures similar to that of clinically approved dose.
GI: Growth Inhibition | p.o.: per oral | o.d.: once daily

Vodobatinib (SCO-088) registration plan alignment with FDA

Vodobatinib being developed under project Frontrunner

- Frontrunner is a program launched to make newer disease modifying therapies in earlier lines of treatment instead of late line setting
- Registration path
  - RP3D determination: Evaluate 2 investigational doses for randomized dose finding (RP3D selection) - 174 mg, the proposed RP2D and lower dose of 87 mg acceptable for evaluation for RP3D selection
  - Randomized control study in earlier line of treatment: Phase 3 study in patients failing >1 TKI may be acceptable for approval
  - Clinical spend expected to increase; due to cost of comparator drug



EOS: End of Study

sparc

Vibozilimod for autoimmune disorders

Siu-Long Yao

Vibozilimod (SCD-044)

Targeting fragmented dermatology market

- Highly selective S1PR1 agonist
- Leading agent in the class under development for Psoriasis and Atopic Dermatitis

Psoriasis	Atopic Dermatitis
US Prevalence ~ 8 mn	US prevalence ~ 18 mn
Dominated by biologics (injectables), limited oral agents being developed for moderate to severe disease	Systemic therapy primarily for moderate to severe disease
Biosimilars yet to take majority share of patients	Usage of JAK inhibitors limited primarily due to black box warning and AE profile

Vibozilimod (SCD-044) for Psoriasis

Phase 2 Study design



- Study open in the US, Latin America and Europe
- 15 sites in the US
- 3 sites in Europe
- Primary endpoint – Proportion of patients with PASI75 response at week 16

PASI: Psoriasis Area and Severity Index

Vibozilimod (SCD-044) for Atopic Dermatitis

Phase 2 Study design



- Study open in the US, Latin America and Europe
- 18 sites in the US
- 15 sites in Europe
- Primary endpoint – Proportion of patients with EASI75 response at week 16

EASI: Eczema Area and Severity Index

Next steps


Futility Analysis
Q2 2024
Interim analysis readout for Atopic Dermatitis study
Q4 2024
Complete data readout for Atopic Dermatitis
Q2 2025

sparc

SCD-153 for Alopecia Areata

Vikram Ramanathan

Alopecia Areata: Autoimmune disease that causes hair loss

Current treatment approaches are limited

Clinical manifestations of Alopecia Areata[1]

- Estimated 6.7 mn people in the US and 160 mn people worldwide have AA[2]
- ~ 50% can experience spontaneous hair regrowth within one year, the majority often relapse

- Current treatments are inadequate
  - Approved JAK1 inhibitors carry black box warning
  - Steroids cause serious AEs: systemic immuno-suppression, muscle wasting, growth retardation in pediatric population

1. Pratt et al. Nat. Rev. Dis. Primers (2017)
2. Natural Alopecia Areata Foundation

SCD-153

Novel topical drug for treatment of Alopecia Areata

SCD-153 blocks key inflammatory cytokines implicated in AA[1]



- SCD-153 inhibits inflammatory chemokines, cytokines and decreases pathogenic CD8+ T cells at base of hair follicle; restores immune privilege at hair follicle
- Being topical treatment should reduce systemic exposure thereby reducing systemic side effects

1. Adapted from Pratt CH, King LE Jr, Messenger AG, Christiano AM, Sundberg JP. Alopecia areata. Nat Rev Dis Primers. 2017;3:17011 | CD8: Cluster of Differentiation 8

SCD-153 has demonstrated promising preclinical data

Hair growth in mouse Alopecia Areata model



n=7; 85–100% alopecia; >45 weeks age
Spontaneous severe C3H/HeJ AA mouse model
Data are represented as mean ± SD; two-way ANOVA followed by Bonferroni's multiple comparisons test (* $p < 0.05$ vs Vehicle)

n=4

#n=1 from each group has completed Week 14

- SCD-153 demonstrates single agent activity
- It also showed suppression of inflammatory markers in skin
- Potential to use in combination with other agents

SCD-153 inhibited IFN signature gene expression in skin of AA diseased mice

sparc

qPCR analysis of AA diseased skin



Data are represented as mean ± SD; n=6–10/group. Outlier's identification by ROUT test. Data were analyzed using Kruskal-Wallis test with post-hoc Dunn's multiple comparisons test; * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001

◆ Naive (Healthy) ● Vehicle, Thrice-a-week ▲ SCD-153, 3%, Thrice-a-week ■ SCD-153, 3%, Twice-a-week

- Significant reduction in IFN signature genes in treated skin at different administered doses was observed
- Suppressed inflammatory markers in skin

FH: Harlequin | qPCR: quantitative Polymerase Chain Reaction

SCD-153 Phase 1 study

A Randomized, Double-Blind, Vehicle-Controlled, Study to Evaluate the Safety, Tolerability and Pharmacokinetics of topically applied SCD-153 in Healthy Volunteers

IND Approved by DCGI



Study Flow Chart

- Phase 1 SAD study initiated in India
- 5 dose levels
- Cohorts administered active drug and placebo

Primary Objective:

- To evaluate the safety and local tolerability

Secondary Objective:

- To evaluate the plasma pharmacokinetics of SCD-153 and its metabolite

DCGI: Drug Controller General of India I IMP: Investigational Medicinal Product

SCD-153: potential to expand in other epidermal diseases



- IFNγ induces CXCL9, CXCL10 & CXCL11 in vitiligous skin. These chemokines recruit pathogenic CD8+ T cells to the pigment-containing melanocyte in the epidermis
- CD8+ T cells release cytokines that destroy the melanocytes causing depigmentation
- *In-vitro* studies have shown that SCD-153 inhibits:
  - Expression of CXCL9, 10 and 11 in stimulated human keratinocytes
  - IFNγ secretion from stimulated murine CD8+ T cells

Image adapted from Picarodo et al. Nat. Rev. Dis. Primers (2015)
CXCL: Chemokine (C-X-C motif) ligand I CXCR3: Chemokine (C-X-C motif) receptor 3

sparc

SBO-154 for multiple cancer indications

Nitin Damle

Antibody drug conjugates

Large market expected to reach ~ 25 bn by 2038

12 FDA
Approved ADCs

US$ 25.34 Bn
Projected ADC market by 2028

24.19% CAGR
from 2023 to 2028

Approved ADCs



SBO-154 (Anti-MUC-1 ADC)

Novel antigen & approach to target MUC1-SEA domain, with an opportunity to therapeutically address multiple cancer indications

- Tumor agnostic opportunity in-licensed from Biomodifying LLC
- SEA targeting hypothesis validated
- Preclinical PoC of anti-tumor efficacy of anti-MUC-1-SEA targeted ADC established
- So far, no directly competing agents targeting MUC1-SEA in clinical development



SEA: Sea urchin sperm protein, enterokinase and agrin | VNTR: Variable Number of Tandem Repeats

SBO-154: Efficacy demonstrated in large established tumors



SBO-154 causes regression of large established tumors with high MUC-1 SEA expression

SBO-154 development update

INTERACT meeting granted by FDA

- INTERACT Meeting (Initial Targeted Engagement for Regulatory Advice on CBER CDER Products) Request
  - Meeting to seek early advice from the FDA to validate preclinical developmental strategy for the IND-enablement of the product and serve as a prelude to Pre-IND meeting prior to IND filing
- FDA response anticipated in November 2023

CBER: Centre for Biologics Evaluation and Research | CDER: Centre for Drug Evaluation and Research

sparc

Financial update

Chetan Rajpara

Financial summary

Year	FY19	FY20	FY21	FY22	FY23	Q1FY24
USD INR	69.95	70.91	74.23	74.49	80.37	82.17
INR Cr						
Total Income	196	87	258	144	250	34
Total Expenses	342	399	410	347	472	129
Profit/(Loss) after Tax	-145	-312	-151	-203	-223	-95
USD Mn						
Total Income	28.1	12.2	34.8	19.3	31.1	4.2
Total Expenses	48.9	56.3	55.2	46.6	58.8	15.8
Profit/(Loss) after Tax	-20.8	-44.1	-20.4	-27.3	-27.7	-11.6

FY: Financial year (April 1st to March 31st)

Cash and liquidity

- Out-licensed SEZABY to SPI Inc. in Q4 2022 and received an upfront sum of US$ 10mn. In addition, SPARC is eligible to receive regulatory and sales linked milestone payments and tiered royalties on sales
- Received ₹703 Cr (US$ 93mn) in Jan-2023 against the conversion of warrants. With this, the entire proceed of the Preferential Issue (i.e. ₹1,112 Cr) stands received
- Cash and cash equivalent as of September 30, 2023 was ₹363 Cr (US$ 44mn)
- The Company has
  (a) Sanctioned bank facilities for ₹175 Cr (US$ 21mn)
  (b) Line of credit from the parent company for ₹250 Cr (US$ 30mn) in place. Utilization of limits as of September 30, 2023 is NIL
- Obtained shareholders' approval in Aug-2023 AGM for raising a sum up to ₹1,800 Cr (US$ 220mn) by way of fresh issuance

THANK YOU

For updates and specific queries,
please visit www.sparc.life or write to us at bus.dev@sparcmail.com

---